Centre informed Supreme Court that providing free gene therapy for Spinal Muscular Atrophy (SMA) could cost India Rs 35-40,000 crore annually. The government has capped free treatment costs at Rs 50 lakh per child annually. Supreme Court allowed continued free treatment at Army R&R hospital for a specific case, but will review broader policy later.